Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells

Trends in Cell Biology

Volumn 24, Issue 8, 2014, Pages 455-463

  Rasola, Andrea ^a   Neckers, Len ^b   Picard, Didier ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cancer metabolism; Chaperones; Mitochondria; ROS; TRAP1

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN 90; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG;

BIOENERGY; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CITRIC ACID CYCLE; CONFORMATIONAL TRANSITION; DOWN REGULATION; HUMAN; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROCESSING; REDOX STRESS; REVIEW; TRANSLATION REGULATION; TUMOR CELL; ANIMAL; ENERGY METABOLISM; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; ENERGY METABOLISM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MITOCHONDRIA; NEOPLASMS; OXIDATIVE PHOSPHORYLATION;

EID: 84904720215     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2014.03.005     Document Type: Review

References (86)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Schulze A., Harris A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012, 491:364-373.
3. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
4. Vander Heiden M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
5. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
6. Warburg O., et al. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8:519-530.
7. Icard P., Lincet H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim. Biophys. Acta 2012, 1826:423-433.
8. Koppenol W.H., et al. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
9. Rodriguez-Enriquez S., et al. The Warburg hypothesis and the ATP supply in cancer cells is oxidative phosphorylation impaired in malignant neoplasias?. Curr. Pharm. Biotechnol. 2012.
10. Barbosa I.A., et al. Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies. Biochim. Biophys. Acta 2012, 1826:238-254.
11. Parks S.K., et al. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 2013, 13:611-623.
12. Dang C.V. Links between metabolism and cancer. Genes Dev. 2012, 26:877-890.
13. Cairns R.A., et al. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
14. Chen J.Q., Russo J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim. Biophys. Acta 2012, 1826:370-384.
15. Frezza C., Gottlieb E. Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol. 2009, 19:4-11.
16. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
17. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21:297-308.
18. Crabtree H.G. Observations on the carbohydrate metabolism of tumours. Biochem. J. 1929, 23:536-545.
19. Diaz-Ruiz R., et al. The Warburg and Crabtree effects: on the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim. Biophys. Acta 2011, 1807:568-576.
20. Miller D.M., et al. c-Myc and cancer metabolism. Clin. Cancer Res. 2012, 18:5546-5553.
21. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8:705-713.
22. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
23. Vousden K.H., Ryan K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.
24. Hensley C.T., et al. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 2013, 123:3678-3684.
25. Caro P., et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 2012, 22:547-560.
26. Ferreira L.M., et al. Metabolic reprogramming of the tumor. Oncogene 2012, 31:3999-4011.
27. Frezza C. The role of mitochondria in the oncogenic signal transduction. Int. J. Biochem. Cell Biol. 2014, 48C:11-17.
28. Mathupala S.P., et al. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim. Biophys. Acta 2010, 1797:1225-1230.
29. Moreno-Sanchez R., et al. Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism. Int. J. Biochem. Cell Biol. 2014, 50C:10-23.
30. Weinberg F., et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8788-8793.
31. Yang M., et al. Oncometabolites: linking altered metabolism with cancer. J. Clin. Invest. 2013, 123:3652-3658.
32. Isaacs J.S., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-153.
33. Selak M.A., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
34. Brahimi-Horn M.C., et al. Hypoxia and energetic tumour metabolism. Curr. Opin. Genet. Dev. 2011, 21:67-72.
35. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
36. Cairns R.A., Mak T.W. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013, 3:730-741.
37. Gasparre G., et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum. Mol. Genet. 2008, 17:986-995.
38. Abu-Amero K.K., et al. High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines. Oncogene 2005, 24:1455-1460.
39. Petros J.A., et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:719-724.
40. Picard D. Preface to Hsp90. Biochim. Biophys. Acta 2012, 1823:605-606.
41. Rohl A., et al. The chaperone Hsp90: changing partners for demanding clients. Trends Biochem. Sci. 2013, 38:253-262.
42. Lavery L.A., et al. Structural asymmetry in the closed state of mitochondrial Hsp90 (TRAP1) supports a two-step ATP hydrolysis mechanism. Mol. Cell 2014, 53:330-343.
43. Leskovar A., et al. The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J. Biol. Chem. 2008, 283:11677-11688.
44. Felts S.J., et al. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem. 2000, 275:3305-3312.
45. Cechetto J.D., Gupta R.S. Immunoelectron microscopy provides evidence that tumor necrosis factor receptor-associated protein 1 (TRAP-1) is a mitochondrial protein which also localizes at specific extramitochondrial sites. Exp. Cell Res. 2000, 260:30-39.
46. Takamura H., et al. TRAP1 controls mitochondrial fusion/fission balance through Drp1 and Mff expression. PLoS ONE 2012, 7:e51912.
47. Costa A.C., et al. Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1/Parkin model of Parkinson's disease. Cell Death Dis. 2013, 4:e467.
48. Zhang L., et al. TRAP1 rescues PINK1 loss-of-function phenotypes. Hum. Mol. Genet. 2013, 22:2829-2841.
49. Hua G., et al. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J. Biol. Chem. 2007, 282:20553-20560.
50. Montesano Gesualdi N., et al. Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress 2007, 10:342-350.
51. Pridgeon J.W., et al. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007, 5:e172.
52. Kang B.H., et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131:257-270.
53. Leav I., et al. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am. J. Pathol. 2010, 176:393-401.
54. Gao J.Y., et al. Correlation between mitochondrial TRAP-1 expression and lymph node metastasis in colorectal cancer. World J. Gastroenterol. 2012, 18:5965-5971.
55. Costantino E., et al. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptosis in human colorectal carcinoma cells. Cancer Lett. 2009, 279:39-46.
56. Masuda Y., et al. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J. Biol. Chem. 2004, 279:42503-42515.
57. Coller H.A., et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:3260-3265.
58. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
59. Yoshida S., et al. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E1604-E1612.
60. Chae Y.C., et al. Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat. Commun. 2013, 4:2139.
61. Chae Y.C., et al. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell 2012, 22:331-344.
62. Sciacovelli M., et al. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab. 2013, 17:988-999.
63. Kang B.H., Altieri D.C. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene 2009, 28:3681-3688.
64. Chiara F., et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS ONE 2008, 3:e1852.
65. Mathupala S.P., et al. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25:4777-4786.
66. Pantic B., et al. Myotonic dystrophy protein kinase (DMPK) prevents ROS-induced cell death by assembling a hexokinase II-Src complex on the mitochondrial surface. Cell Death Dis. 2013, 4:e858.
67. Robey R.B., Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006, 25:4683-4696.
68. Fan A.C., et al. Hsp90 functions in the targeting and outer membrane translocation steps of Tom70-mediated mitochondrial import. J. Biol. Chem. 2006, 281:33313-33324.
69. Faou P., Hoogenraad N.J. Tom34: a cytosolic cochaperone of the Hsp90/Hsp70 protein complex involved in mitochondrial protein import. Biochim. Biophys. Acta 2012, 1823:348-357.
70. Young J.C., et al. Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell 2003, 112:41-50.
71. Zara V., et al. Mitochondrial carrier protein biogenesis: role of the chaperones Hsc70 and Hsp90. Biochem. J. 2009, 419:369-375.
72. Finley D.S., et al. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011, 16(Suppl. 2):4-13.
73. Rasola A., et al. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:726-731.
74. Tochhawng L., et al. Redox regulation of cancer cell migration and invasion. Mitochondrion 2013, 13:246-253.
75. Kubota K., et al. Tumor necrosis factor receptor-associated protein 1 regulates cell adhesion and synaptic morphology via modulation of N-cadherin expression. J. Neurochem. 2009, 110:496-508.
76. Caino M.C., et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J. Clin. Invest. 2013, 123:2907-2920.
77. Matassa D.S., et al. Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1. Cell Death Dis. 2013, 4:e851.
78. Song H.Y., et al. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. J. Biol. Chem. 1995, 270:3574-3581.
79. Exner N., et al. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012, 31:3038-3062.
80. Corti O., Brice A. Mitochondrial quality control turns out to be the principal suspect in Parkin and PINK1-related autosomal recessive Parkinson's disease. Curr. Opin. Neurobiol. 2013, 23:100-108.
81. Butler E.K., et al. The mitochondrial chaperone protein TRAP1 mitigates alpha-Synuclein toxicity. PLoS Genet. 2012, 8:e1002488.
82. Xu L., et al. Overexpression of mitochondrial Hsp70/Hsp75 in rat brain protects mitochondria, reduces oxidative stress, and protects from focal ischemia. J. Cereb. Blood Flow Metab. 2009, 29:365-374.
83. 2+-dependent apoptosis and necrosis. Cell Calcium 2011, 50:222-233.
84. Xiang F., et al. Mitochondrial chaperone tumour necrosis factor receptor-associated protein 1 protects cardiomyocytes from hypoxic injury by regulating mitochondrial permeability transition pore opening. FEBS J. 2010, 277:1929-1938.
85. Saisawat P., et al. Whole-exome resequencing reveals recessive mutations in TRAP1 in individuals with CAKUT and VACTERL association. Kidney Int. 2013, 10.1038/ki.2013.417.
86. Aust S., et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer - a study of the OVCAD consortium. Mol. Cancer 2012, 11:69.